Josephine Cardarelli

7662381, Feb 16, 2010

Jun 20, 2005

11/157494

Josephine M. Cardarelli - San Carlos CA, US
Alison Witte - Scotts Valley CA, US
Mohan Srinivasan - San Jose CA, US

Medarex, Inc. - Princeton NJ

A61K 39/395
C12P 21/08

4241431, 53038822

The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

7875278, Jan 25, 2011

Feb 17, 2006

11/918191

Josephine M. Cardarelli - San Carlos CA, US
David B. Passmore - San Carlos CA, US
Jenny Albanese - South Lake Tahoe CA, US
Lei Zhu - Bellevue WA, US

Medarex, Inc. - Princeton NJ

A61K 39/00

4241331, 4241381, 4241551, 4241741, 435375, 5303873, 5303877, 5303888

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.

7888484, Feb 15, 2011

Sep 29, 2009

12/569205

Josephine M. Cardarelli - San Carlos CA, US
Tseng-hui Timothy Chen - Burlingame CA, US
David King - Belmont CA, US
Christopher R. Bebbington - San Mateo CA, US
Sarah Lee Pogue - Fremont CA, US
Francis J. Carr - Aberdeenshire, GB
Stephen Williams - Aberdeenshire, GB

Medarex, Inc. - Princeton NJ

C07K 16/24

53038823, 5303887

Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.

8008449, Aug 30, 2011

May 2, 2006

11/913217

Alan J. Korman - Piedmont CA, US
Mohan Srinivasan - San Jose CA, US
Changyu Wang - Fremont CA, US
Mark J. Selby - San Francisco CA, US
Josephine M. Cardarelli - San Carlos CA, US

Medarex, Inc. - Princeton NJ
Ono Pharmaceutical Co., Ltd. - Osaka

C07K 16/28

53038815

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

8097703, Jan 17, 2012

Jun 20, 2006

11/917750

David John King - Belmont CA, US
Jie Liu - Palo Alto CA, US
Haichun Huang - Fremont CA, US
David B. Passmore - San Carlos CA, US
Alasdair Fraser Bell - Mountain View CA, US
Josephine M. Cardarelli - San Carlos CA, US
Chin Pan - Los Altos CA, US
To Uyen Thi Do - Sacramento CA, US
Sharline Chen - Sunnyvale CA, US
Dawn M. Tanamachi - Milpitas CA, US

Medarex, Inc. - Princeton NJ

C07K 16/00
C07K 17/00
C12P 21/08
C07K 14/00

5303871, 5303873, 5303877, 5303879, 5303881, 53038815, 53038822, 5303887, 53038873, 5303911

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.

8124738, Feb 28, 2012

Sep 26, 2006

12/065436

Jonathan Alexander Terret - Los Altos CA, US
Li-sheng Lu - Mountain View CA, US
David John King - Belmont CA, US
Josephine M. Cardarelli - San Carlos CA, US
Chin Pan - Los Altos CA, US
Haichun Huang - Fremont CA, US
Marco A. Coccia - Scotts Valley CA, US

Medarex, Inc. - Princeton NJ

C07K 16/00
A61K 39/395
A61K 39/00

5303871, 5303877, 5303881, 53038815, 53038873, 53038875, 5303888, 53038885, 5303911, 4241411, 4241421, 4241521, 4241541, 4241551, 4241561

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.

8258266, Sep 4, 2012

May 27, 2009

12/472877

Shrikant Deshpande - Fremont CA, US
Haichun Huang - Fremont CA, US
Mohan Srinivasan - Cupertino CA, US
Josephine M. Cardarelli - San Carlos CA, US
Changyu Wang - Fremont CA, US
David B. Passmore - San Carlos CA, US
Vangipuram Rangan - Pleasant Hill CA, US
Thomas E. Lane - Irvine CA, US
Hans S. Keirstead - Irvine CA, US
Michael T. Liu - Irvine CA, US

Medarex, Inc. - Princeton NJ

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/40
C12N 5/02
C12N 5/16
C07K 1/00

5303871, 5303873, 5303879, 5303881, 53038815, 5303882, 53038823, 5303911, 4241301, 4241321, 4241341, 4241361, 4241391, 4241411, 4241421, 4241581, 4241781, 435325, 435326, 435328, 435331, 435335

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

8383118, Feb 26, 2013

Dec 8, 2006

12/095557

Cynthia A. Vistica - Dublin CA, US
Eric H. Holmes - Bothell WA, US
Peter Brams - Sacramento CA, US
Alison Witte - Scotts Valley CA, US
Josephine M. Cardarelli - San Carlos CA, US

Medarex, Inc. - Princeton NJ

A61K 39/395
A61K 39/40
C07K 16/00

4241411, 4241781, 5303881

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.